NEENAH, Wis. (WBAY) - Neenah-Menasha Fire Rescue kept a fire in an apartment building from spreading outside of where the fire started. Firefighters responded to a call to the apartment building ...

Shattuck Park, Neenah Farmer's Market, 210 E Wisconsin Ave, Neenah, WI 54956, United States,Neenah, Wisconsin View on map ...

Analyst Price Forecast Suggests 770.40% Upside As of September 25, 2024, the average one-year price target for Shattuck Labs is $10.88/share. The forecasts range from a low of $8.08 to a high of ...

Ashley Park vibrates with energy and warmth like a downed power line on a beautiful summer night. Spending time with Ashley is a cross between Paris Fashion Week, one of those dancing inflatables ...

Shattuck Labs ( (STTK) ) just unveiled an announcement. Shattuck Labs, Inc. has decided to terminate its collaboration with Ono Pharmaceutical and discontinue the clinical program for SL-172154 ...

Shattuck Labs Inc.’s stock fell 43% Tuesday to put it on track for its biggest-ever one-day percentage decline, after the biotech said it’s scrapping its main product candidate after a failed ...

Shattuck Labs shares slid more than 40% and hit an all-time low on Tuesday after the biotechnology company threw in the towel on its lead program and unveiled a restructuring that will eliminate ...

Shattuck Labs (NASDAQ:STTK) fell ~58% in the premarket on Tuesday after the company announced the discontinuation of its lead experimental therapy SL-172154 following disappointing early-stage ...

Shat­tuck Labs is lay­ing off 40% of its work­force and dis­con­tin­u­ing its CD47 pro­gram in acute myeloid leukemia and high­er-risk myelodys­plas­tic syn­dromes fol­low­ing dis ...

(RTTNews) - Shattuck Labs (STTK) announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The company will turn its focus to SL-325 ...

On Tuesday, Shattuck Labs, Inc. (NASDAQ:STTK) stock traded lower, with a session volume of 9.48 million versus the average volume of 328.32k. The company announced a strategic pipeline prioritization.

Shattuck Labs Inc. opted, as one analyst put the matter, to do “the right thing early” by ending the clinical program with phase I-stage SL-172154 and shift resources to SL-325, a death receptor 3 ...